BETA-LACTAMASE-HEMMER
European patent · EP3882252 · In force
Register entry
- Publication number
- EP3882252
- Application number
- EP21157549
- Kind
- European patent with effect for Switzerland and Liechtenstein
- Status
- In force
- Specification
- Granted
- Filed
- Jun 11, 2015
- Published
- Sep 22, 2021
- Granted
- Nov 19, 2025
- Protection ends at the latest
- Jun 10, 2035
- Next annual fee due
- Jun 30, 2026
- IPC classes
- C07F 5/02 (2006.01)A61K 31/69 (2006.01)A61K 31/43 (2006.01)A61P 31/00 (2006.01)
- Priority
- US 201462010969 P 11.06.2014US 201462010940 P 11.06.2014US 201462010968 P 11.06.2014US 201562118227 P 19.02.2015
- Divided from
- EP15806746
- Filing language
- English
- Source
- Swissreg
History
What the Federal Institute of Intellectual Property published about this title, newest first.
- Sep 30, 2026
Change
Published in Swissreg on 30.09.2026
- Apr 16, 2026
Owner
- Owner
- Venatorx Pharmaceuticals, Inc., 30 Spring Mill Drive, Malvern, PA 19355, USA → Basilea Pharmaceutica International AG, Allschwil, Hegenheimermattweg 167b, 4123 Allschwil
Published in Swissreg on 16.04.2026
- Nov 19, 2025
Granted
- Specification status
- Non-published patent application → Granted patent
- Status of protective title
- Initiated → Active
Published in Swissreg on 19.11.2025
Parties
Inventor
BURNS, Christopher J.
Malvern, Pennsylvania 19355, US
DAIGLE, Denis
Maryland 21154, US
LIU, Bin
Dayton, New Jersey 08810, US
JACKSON, Randy W.
Livingston, Montana 59047, US
HAMRICK, Jodie
New Holland, Pennsylvania 17557, US
MCGARRY, Daniel
Malvern, Pennsylvania 19355, US
PEVEAR, Daniel C.
Downingtown, Pennsylvania 19335, US
TROUT, Robert E. Lee
Collegeville, Pennsylvania 19426, US
The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.